Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitae's Debt Financing: Crucial Lifeline in a Tightening Financial Market

This article was originally published in Start Up

Executive Summary

Roughly one week after GlaxoSmithKline gave Vitae Pharmaceuticals back rights to its renin inhibitor, the biotech signed a $13 million loan deal with Silicon Valley Bank and Oxford Finance, providing a cash runway at least into 2010. The cash lifeline was relatively small in dollar value but significant for even happening in the first place. The hard economic times have all but shut down the venture capital supply, leaving serious questions about money strategies for other biotechs.
Advertisement

Related Content

Autoimmune RORγt Program May Portend Change Of Direction For Vitae
Best of the Blog: START-UP May/June 2009
Best of the Blog: START-UP May/June 2009
Best of the IN VIVO Blog, October 2008
Can Big Pharma Save Biotech Investors?
Can Big Pharma Save Biotech Investors?
Best of the IN VIVO Blog, October 2008
Can Big Pharma Save Biotech Investors?
Pfizer Restructures for a More Flexible Future

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel